|
1
|
de Bono JS, Logothetis CJ, Molina A,
Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F,
et al: Abiraterone and increased survival in metastatic prostate
cancer. N Engl J Med. 364:1995–2005. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tannock IF, de Wit R, Berry WR, Horti J,
Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, et
al: Docetaxel plus prednisone or mitoxantrone plus prednisone for
advanced prostate cancer. N Engl J Med. 351:1502–1512. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
James ND, Sydes MR, Clarke NW, Mason MD,
Dearnaley DP, Spears MR, Ritchie AW, Parker CC, Russell JM, Attard
G, et al: Addition of docetaxel, zoledronic acid, or both to
first-line long-term hormone therapy in prostate cancer (STAMPEDE):
Survival results from an adaptive, multiarm, multistage, platform
randomized controlled trial. Lancet. 387:1163–1177. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fizazi K, Tran N, Fein L, Matsubara N,
Rodriguez-Antolin A, Alekseev BY, Özgüroğlu M, Ye D, Feyerabend S,
Protheroe A, et al: Abiraterone plus prednisone in metastatic,
castration-sensitive prostate cancer. N Engl J Med. 377:352–360.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Leppert W and Buss T: The role of
corticosteroids in the treatment of pain in cancer patients. Curr
Pain Headache Rep. 16:307–313. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Khandwala HM, Vassilopoulou-Sellin R,
Logethetis CJ and Friend KE: Corticosteroid-induced inhibition of
adrenal androgen production in selected patients with prostate
cancer. Endocr Pract. 7:11–15. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Eichholz A, Ferraldeschi R, Attard G and
de Bono JS: Putting the brakes on continued androgen receptor
signaling in castration resistant prostate cancer. Mol Cell
Endocrinol. 360:68–75. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Komiya A, Shimbo M, Suzuki H, Imamoto T,
Kato T, Fukasawa S, Kamiya N, Naya Y, Mori I and Ichikawa T: Oral
low-dose dexamethasone for androgen-independent prostate cancer
patients. Oncol Lett. 1:73–79. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Venkitaraman R, Lorente D, Murthy V,
Thomas K, Parker L, Ahiabor R, Dearnaley D, Huddart R, De Bono J
and Parker C: A randomised phase 2 trial of dexamethasone versus
prednisolone in castration-resistant prostate cancer. Eur Urol.
67:673–679. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lorente D, Omlin A, Ferraldeschi R, Pezaro
C, Perez R, Mateo J, Altavilla A, Zafeirou Z, Tunariu N, Parker C,
et al: Tumour responses following a steroid switch from prednisone
to dexamethasone in castration resistant prostate cancer patients
progressing on abiraterone. Br J Cancer. 111:2248–2253. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Schmid S, Fornaro J, Rothermundt C, Omlin
A, Brändle M, Rupp NJ and Gillessen S: Abiraterone-what is wrong
with the adrenal glands? Clin Genitourin Cancer. 12:e133–e137.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tannock I, Gospodarowicz M, Meakin W,
Panzarella T, Stewart L and Rider W: Treatment of metastatic
prostatic cancer with low-dose prednisone: Evaluation of pain and
quality of life as pragmatic indices of response. J Clin Oncol.
7:590–597. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Venkitaraman R, Thomas K, Huddart RA,
Horwich A, Dearnaley DP and Parker CC: Efficacy of low-dose
dexamethasone in castration-refractory prostate cancer. BJU Int.
101:440–443. 2008.PubMed/NCBI
|
|
14
|
De Santis M and Saad F: Practical guidance
on the role of corticosteroids in the treatment of metastatic
castration resistant prostate cancer. Urology. 96:156–164. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Weitzman AL, Shelton G, Zuech N, Owen CE,
Judge T, Benson M, Sawczuk I, Katz A, Olsson CA, Bagiella E, et al:
Dexamethasone does not significantly contribute to the response
rate of docetaxel and estramustine in androgen independent prostate
cancer. J Urol. 163:834–837. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Diederich S, Scholz T, Eigendorff E,
Bumke-Vogt Ch, Quinkler M, Exner P, Pfeiffer AF, Oelkers W and Bähr
V: Pharmacodynamics and pharmacokinetics of synthetic
mineralocorticoids and glucocorticoids: Receptor transactivation
and prereceptor metabolism by 11beta-hydroxysteroid-dehydrogenases.
Horm Metab Res. 36:423–429. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nishimura K, Nonomura N, Yasunaga Y,
Takaha N, Inoue H, Sugao H, Yamaguchi S, Ukimura O, Miki T and
Okuyama A: Low doses of oral dexamethasone for hormone-refractory
prostate carcinoma. Cancer. 89:2570–2576. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Crona DJ and Whang YE: Androgen
receptor-dependent and -independent mechanisms involved in prostate
cancer therapy resistance. Cancers (Basel). 9(pii): E672017.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Arora VK, Schenkein E, Murali R, Subudhi
SK, Wongvipat J, Balbas MD, Shah N, Cai L, Efstathiou E, Logothetis
C, et al: Glucocorticoid receptor confers resistance to
antiandrogens by bypassing androgen receptor blockade. Cell.
155:1309–1322. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lan NC, Graham B, Bartter FC and Baxter
JD: Binding of steroids to mineralocorticoid receptors:
Implications for in vivo occupancy by glucocorticoids. J Clin
Endocrinol Metab. 54:332–342. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dovio A, Sartori ML, De Francia S, Mussino
S, Perotti P, Saba L, Abbadessa G, Racca S and Angeli A:
Differential expression of determinants of glucocorticoid
sensitivity in androgen-dependent and androgen-independent human
prostate cancer cell lines. J Steroid Biochem Mol Biol. 116:29–36.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Leach DA, Powell SM and Bevan CL: Women in
Cancer Thematic Review: New roles for nuclear receptors in prostate
cancer. Endocr Relat Cancer. 23:T85–T108. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Taplin ME, Bubley GJ, Shuster TD, Frantz
ME, Spooner AE, Ogata GK, Keer HN and Balk SP: Mutation of the
androgen-receptor gene in metastatic androgen-independent prostate
cancer. N Engl J Med. 332:1393–1398. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhao XY, Malloy PJ, Krishnan AV, Swami S,
Navone NM, Peehl DM and Feldman D: Glucocorticoids can promote
androgen-independent growth of prostate cancer cells through a
mutated androgen receptor. Nat Med. 6:703–706. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Richards J, Lim AC, Hay CW, Taylor AE,
Wingate A, Nowakowska K, Pezaro C, Carreira S, Goodall J, Arlt W,
et al: Interactions of abiraterone, eplerenone, and prednisolone
with wild-type and mutant androgen receptor: A rationale for
increasing abiraterone exposure or combining with MDV3100. Cancer
Res. 72:2176–2182. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nishimura K, Nonomura N, Satoh E, Harada
Y, Nakayama M, Tokizane T, Fukui T, Ono Y, Inoue H, Shin M, et al:
Potential mechanism for the effects of dexamethasone on growth of
androgen-independent prostate cancer. J Natl Cancer Inst.
93:1739–1746. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lam JS, Leppert JT, Vemulapalli SN,
Shvarts O and Belldegrun AS: Secondary hormonal therapy for
advanced prostate cancer. J Urol. 175:27–34. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yano A, Fujii Y, Iwai A, Kageyama Y and
Kihara K: Glucocorticoids suppress tumor angiogenesis and in vivo
growth of prostate cancer cells. Clin Cancer Res. 12:3003–3009.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Akakura K, Suzuki H, Ueda T, Komiya A,
Ichikawa T, Igarashi T and Ito H: Possible mechanism of
dexamethasone therapy for prostate cancer: Suppression of
circulating level of interleukin-6. Prostate. 56:106–109. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ueda T, Bruchovsky N and Sadar MD:
Activation of the androgen receptor N-terminal domain by
interleukin-6 via MAPK and STAT3 signal transduction pathways. J
Biol Chem. 277:7076–7085. 2002. View Article : Google Scholar : PubMed/NCBI
|
